Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab
| Registry | NCT04247906 |
|---|---|
| Status | Approved for marketing |
| Study type | Expanded access |
| Sponsor | Omeros Corporation (Industry); collaborators: Impatients N.V. trading as myTomorrows |
| Conditions | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) |
| Interventions | Narsoplimab (Drug) |
| Dates | first posted 2020-01-30, last updated 2026-03-05 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) All trials of Narsoplimab
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.
Sex: All
* Patient (adult or pediatric) must have undergone allogeneic or autologous hematopoietic stem cell transplant (HSCT) * Patient must be capable of understanding an informed consent form (ICF) or the parent or legal guardian of the patient is able to understand and sign a written ICF prior to the initiation of any treatment procedures. * Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of microangiopathic hemolytic anemia.